The trial results demonstrated that AK112 combined with platinum-based doublet therapy showed promising anti-tumor activity and safety, serving as the first-line treatment in advanced NSCLC patients without driver mutations as well as in patients with EGFR functional mutations who have failed previous EGFR-TKI therapy, and in advanced NSCLC patients who had failed prior systemic platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. This evidence concerns the gene CD274 and neoplasm.